Novartis Reports Results of Mayzent (siponimod) in P-III EXPAND Study for Secondary Progressive Multiple Sclerosis

Shots:

• The P-III EXPAND study involves assessing of Mayzent vs PBO in 1,651 patients with SPMS from 31 countries with varying levels of disability (Core Part), EDSS scores of 3·0–6·5, followed by extended treatment with open-label BAF312 to evaluate long-term safety, tolerability and efficacy
• The P-III EXPAND study: 52% reduction in ARR in Mayzent group; reduction in the risk of 3mos. & 6mos. CDP; no differences in Timed 25-Foot Walk Test; 79% reduction in T2 lesion volume; 55% reduction in ARR; patients free from Gd-enhancing lesions & enlarging T2 lesions (89% vs 67% & 57% vs 37%). Post-hoc analysis from EXPAND study demonstrated a reduction in cGM and thalamic atrophy
• Mayzent is a S1P receptor modulator targeting S1P1 and S1P5 receptors, approved in multiple countries including the US for RMS, EU, Australia, Albania for SPMS, Canada and UAE for active SPMS whereas Switzerland, Japan and China regulatory filings are in progress

Click here to­ read full press release/ article | Ref: Novartis | Image: StraitTimes